Bafna Pharmaceuticals Ltd vs Balaxi Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 131.85 as of 05 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Balaxi Pharmaceuticals Ltd changed from 13.8 on March 2021 to 14.1 on March 2025 . This represents a CAGR of 0.43% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Balaxi Pharmaceuticals Ltd changed from ₹ 524.5 crore on March 2021 to ₹ 352.89 crore on March 2025 . This represents a CAGR of -7.62% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Balaxi Pharmaceuticals Ltd for the Dec '25 is ₹ 72.64 crore as compare to the Sep '25 revenue of ₹ 57.76 crore. This represent the growth of 25.76% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Balaxi Pharmaceuticals Ltd for the Dec '25 is ₹ 3.19 crore as compare to the Sep '25 ebitda of ₹ 2.75 crore. This represent the growth of 16% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Balaxi Pharmaceuticals Ltd changed from ₹ 6.48 crore to ₹ 0.31 crore over 7 quarters. This represents a CAGR of -82.40% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Balaxi Pharmaceuticals Ltd changed from 3.41 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited was initially incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942.
The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017 and further changed to Balaxi Pharmaceuticals Limited in 2021.
Initially, the Company was incorporated with the object of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading.
The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Balaxi Pharmaceuticals Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Balaxi Pharmaceuticals Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 311 Cr while Market cap of Balaxi Pharmaceuticals Ltd is 150 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Balaxi Pharmaceuticals Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Balaxi Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Balaxi Pharmaceuticals Ltd?

As of May 5, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹131.85. On the other hand, Balaxi Pharmaceuticals Ltd stock price is INR ₹27.17.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Balaxi Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Balaxi Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.